Anti-eryptotic Effect of a Food Supplement With Plants Sterols in Hypercholesterolemia Treated With Statins

Anti-eryptotic Effect of Regular Intake of a Food Supplement With Plants Sterols in Subjects With Hypercholesterolemia Treated With Statins

Potential anti-eryptotic effect of a regular intake of a plant sterol (PS)-containing food supplement, in moderate hypercholesterolemic patients treated with the PS-containing food supplement or placebo supplement.

Study Overview

• Status: Recruiting
• Conditions: Cardiovascular Diseases; Atherosclerosis; Hypercholesterolemia
• Intervention / Treatment: Dietary supplement: PS-containing dietary supplement; Other: Placebo

Detailed Description

Oxidative damage has been related to the externalization of phosphatidylserine in erythrocytes, an event associated with eryptosis (programmed death of erythrocytes). In addition, an increase in eryptosis has been observed in patients with hypercholesterolaemia. PS-enriched food supplements could be a nutritional strategy to improve risk factors in patients with moderate hypercholesterolemia treated with statins, constituting a synergistic treatment with these drugs. The present study aims to evaluate the eryptotic process (externalization of phosphatidylserine) after regular intake of a food supplement containing PS (2g/day) in patients with moderate hypercholesterolemia treated with statins. This is a case-control study with 32 cases (intake or a PS-containing food supplement) and 16 controls (placebo intake based on the excipient), with an intervention period of 6 weeks. The evaluation of eryptosis is carried out by determining the externalization of phosphatidylserine, the size of the erythrocytes and an ex vivo assay of adhesion of eryptotic erythrocytes to the vascular endothelium. In addition, the redox state (GSH), the in vivo oxidation of cholesterol (COPs), and biochemical and hematological parameters are evaluated. All parameters are evaluated at the beginning (week 0) and at the end of the intervention period (week 6).

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Amparo Asunción Alegría Torán, Professor; Phone Number: +34 963544907; Email: amparo.alegria@uv.es

Study Locations

• Spain
  • Valencia, Spain, 46010
    • Recruiting
    • Hospital Clínico Universitario de Valencia
    • Contact: Sergio Martínez Hervás; Phone Number: 961625694; Email: sergio.martinez@uv.es

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants with hypercholesterolemia (LDL cholesterol ≥ 160mg/dl at the time of diagnosis), receiving treatment with moderate intensity statins (atorvastatin 10-20 mg or simvastatin 20-40 mg or rosuvastatin 5-10 mg)
• No previous episodes of cardiovascular disease
• Absence of other analytical abnormalities or previous illnesses

Exclusion Criteria:

• Diabetes mellitus
• Participants in secondary prevention
• Treatment with lipid-lowering drugs other than atorvastatin, simvastatin or rosuvastatin
• Liver disease
• Renal failure
• Uncontrolled hypothyroidism
• Smokers
• Participants consuming foods enriched with PS or food supplements that contain PS

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PS-containing dietary supplement; Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)	Dietary supplement: PS-containing dietary supplement; Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
Placebo Comparator: Placebo; Sachet containing the excipients of the ingredient (2,25 g placebo/day)	Other: Placebo; Sachet containing the excipients of the ingredient (2,25 g placebo/day)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in the externalization of phosphatidylserine	The externalization of phosphatidylserine, assessed by flow cytometry (Kit Annexin V) with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in the adhesion to the endothelium by eryptotic erythrocytes	The adhesion to the endothelium by eryptotic erythrocytes, assessed with parallel-plate flow chamber technique in human umbilical vein endothelial cells (HUVECs) with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in cell size ('forward scatter')	Cell size, assessed by flow cytometry with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in reduced glutathione cellular levels (GSH)	GSH, assessed by flow cytometry (Green CMFDA), with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic levels of cholesterol oxidation products (COPs)	COPs levels, assessed by gas chromatography-mass spectometry, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic glucose	Glucose, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic total cholesterol	Total cholesterol, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic HDL-c	HDL-c, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic LDL-c	LDL-c, calculated by the Friedewald's formula, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic triglycerides	Triglycerides, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic Apo A	Apo A, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic Apo B	Apo B, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic High-sensitivity C-reactive protein (hsCRP)	hs CRP, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic insulin	Insulin, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Changes in plasmatic Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)	HOMA-IR, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention)	0 and 6 weeks
Evaluation of the mediterranean diet adherence to measure quality of life	Mediterranean diet adherence screener (MEDAS) is used, consisting in 14 questions (each one 0 or 1 point, final score between 0 and 14). Results are ranged between 0-7 points (low adherence), 7-10 (moderate adherence), and 10-14 (high adherence). This is only evaluated at the beginning of the intervention.	0 weeks
Evaluation of the physical activity to measure quality of life	International physical activity questionaire-short form (IPAC-SF) is used, consisting in 7 questions. Intensity, frequency and duration of the exercise are evaluated through metabolic equivalent of task (METs). This allows to differentiate 3 levels of physical activity: Low: Not enough activity to achieve the next level Moderate: 3 or more days of vigorous physical activity for at least 20 minutes per day, 5 or more days of moderate physical activity and/or walking at least 30 minutes per day, or 5 or more days of any combination of walking, moderate or vigorous physical activity achieving at least a total of 600 METs High: Vigorous physical activity at least 3 days per week achieving a total of at least 1500 METs, or 7 days of any combination of walking, with moderate and/or vigorous physical activity, achieving a total of at least 3000 METs This is only evaluated at the beginning of the intervention.	0 weeks

Collaborators and Investigators

• Sponsor: University of Valencia
• Collaborators: University of Bologna; Hospital Clínico Universitario de Valencia
• Investigators: Principal Investigator: Amparo Asunción Alegría Torán, Professor, University of Valencia

Publications and helpful links

General Publications

• Cilla A, Lopez-Garcia G, Collado-Diaz V, Amparo Blanch-Ruiz M, Garcia-Llatas G, Barbera R, Martinez-Cuesta MA, Real JT, Alvarez A, Martinez-Hervas S. Hypercholesterolemic patients have higher eryptosis and erythrocyte adhesion to human endothelium independently of statin therapy. Int J Clin Pract. 2021 Nov;75(11):e14771. doi: 10.1111/ijcp.14771. Epub 2021 Sep 7.
• Restivo I, Attanzio A, Tesoriere L, Allegra M, Garcia-Llatas G, Cilla A. Anti-Eryptotic Activity of Food-Derived Phytochemicals and Natural Compounds. Int J Mol Sci. 2022 Mar 11;23(6):3019. doi: 10.3390/ijms23063019.

Study record dates

Study Major Dates

• Study Start (Actual): October 19, 2023
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): May 1, 2024

Study Registration Dates

• First Submitted: May 8, 2023
• First Submitted That Met QC Criteria: June 2, 2023
• First Posted (Actual): June 13, 2023

Study Record Updates

• Last Update Posted (Actual): November 29, 2023
• Last Update Submitted That Met QC Criteria: November 28, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Cholesterol; Plant Sterols; Eryptosis; Cholesterol oxidation products
• Additional Relevant MeSH Terms: Vascular Diseases; Metabolic Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Lipid Metabolism Disorders; Hyperlipidemias; Dyslipidemias; Cardiovascular Diseases; Hypercholesterolemia; Atherosclerosis
• Other Study ID Numbers: BIONUTEST_2023/069; PID2019-104167RB-I00 (Other Grant/Funding Number: MCIN/AEI/10.13039/501100011033)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No